Viking Therapeutics (VKTX) EBITDA (2014 - 2026)

Viking Therapeutics has disclosed EBITDA across 13 years of filings, most recently posting -$159.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$159.6 million, down 254.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$473.0 million (down 272.85% YoY), and the FY2025 annual result was -$358.5 million, down 224.82% from the prior year.
• EBITDA came in at -$159.6 million for Q1 2026 at Viking Therapeutics, down from -$157.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$15.9 million in Q3 2022 to a low of -$159.6 million in Q1 2026.
• The 5-year median for EBITDA is -$22.9 million (2024), against an average of -$46.1 million.
• Across the five-year window, EBITDA climbed 6.09% in 2024 and slumped 329.01% in 2025, its largest moves.
• Viking Therapeutics' EBITDA stood at -$18.9 million in 2022, then slipped by 27.46% to -$24.1 million in 2023, then plunged by 57.07% to -$37.8 million in 2024, then plunged by 316.68% to -$157.7 million in 2025, then dropped by 1.21% to -$159.6 million in 2026.
• The last three EBITDA figures came in at -$159.6 million (Q1 2026), -$157.7 million (Q4 2025), and -$90.2 million (Q3 2025), per Business Quant data.